Point72 (DIFC)’s Immunome IMNM Stock Holding History

Point72 (DIFC)’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,275	Closed	-$77.3K	–	1858
2024 Q4	$77.3K	Buy	+7,275	New	+$87.9K	﹤0.01%	1050

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Point72 (DIFC)'s IMNM Position: Q1 2025 in Review

Point72 (DIFC) sold out of Immunome (IMNM) in Q1 2025, closing a stake of 7,275 shares — an estimated $77.3K sold.

Point72 (DIFC) first reported a position in IMNM in Q4 2024 and held it in 1 quarter. The position peaked at $77.3K in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

Point72 (DIFC) reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 7,275 Immunome shares in Q1 2025, an estimated $77.3K.
Point72 (DIFC) first reported a position in Immunome in Q4 2024 and held it in 1 quarter.
Point72 (DIFC)'s Immunome position peaked at $77.3K in Q4 2024.
142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.